Compare Stocks: PRTA, VIR, KLRA, and RXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KLRA Kailera Therapeutics	$12.70 -5.6%	$17.53	$12.47 ▼ $28.23	$1.65B	N/A	736,700 shs	1.13 million shs
PRTA Prothena	$8.24 -1.1%	$8.98	$7.73 ▼ $11.80	$431.39M	-0.33	501,101 shs	398,335 shs
RXRX Recursion Pharmaceuticals	$3.19 -1.5%	$3.27	$2.77 ▼ $7.18	$1.71B	1.07	17.89 million shs	14.75 million shs
VIR Vir Biotechnology	$10.52 +0.8%	$9.84	$4.78 ▼ $11.94	$1.78B	1.63	2.44 million shs	2.09 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KLRA Kailera Therapeutics	-2.18%	-18.14%	-25.03%	-29.69%	+1,344,999,900.00%
PRTA Prothena	-5.98%	-12.68%	-5.98%	-1.88%	+2.08%
RXRX Recursion Pharmaceuticals	-4.99%	-5.81%	+2.53%	+4.18%	-32.08%
VIR Vir Biotechnology	-3.06%	-6.62%	+12.99%	+12.26%	+117.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KLRA Kailera Therapeutics	$12.70 -5.6%	$17.53	$12.47 ▼ $28.23	$1.65B	N/A	736,700 shs	1.13 million shs
PRTA Prothena	$8.24 -1.1%	$8.98	$7.73 ▼ $11.80	$431.39M	-0.33	501,101 shs	398,335 shs
RXRX Recursion Pharmaceuticals	$3.19 -1.5%	$3.27	$2.77 ▼ $7.18	$1.71B	1.07	17.89 million shs	14.75 million shs
VIR Vir Biotechnology	$10.52 +0.8%	$9.84	$4.78 ▼ $11.94	$1.78B	1.63	2.44 million shs	2.09 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KLRA Kailera Therapeutics	-2.18%	-18.14%	-25.03%	-29.69%	+1,344,999,900.00%
PRTA Prothena	-5.98%	-12.68%	-5.98%	-1.88%	+2.08%
RXRX Recursion Pharmaceuticals	-4.99%	-5.81%	+2.53%	+4.18%	-32.08%
VIR Vir Biotechnology	-3.06%	-6.62%	+12.99%	+12.26%	+117.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	236.88% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	196.94% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	153.86% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$21.57	106.33% Upside

Current Analyst Ratings Breakdown

Latest PRTA, VIR, KLRA, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/14/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
7/28/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	PRTA Prothena	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
7/17/2026	RXRX Recursion Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	$54.53M	7.94	N/A	N/A	$5.21 per share	1.59
RXRX Recursion Pharmaceuticals	$74.68M	22.76	N/A	N/A	$2.14 per share	1.48
VIR Vir Biotechnology	$68.56M	25.81	N/A	N/A	$5.50 per share	1.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.12	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	11/4/2026 (Estimated)

Latest PRTA, VIR, KLRA, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KLRA Kailera Therapeutics	N/A	11.11	11.11
PRTA Prothena	N/A	25.05	25.05
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KLRA Kailera Therapeutics	N/A
PRTA Prothena	97.08%
RXRX Recursion Pharmaceuticals	89.06%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
KLRA Kailera Therapeutics	N/A
PRTA Prothena	10.40%
RXRX Recursion Pharmaceuticals	6.65%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A
PRTA Prothena	67	52.35 million	46.91 million	Optionable
RXRX Recursion Pharmaceuticals	600	535.34 million	499.74 million	Optionable
VIR Vir Biotechnology	367	169.22 million	164.31 million	Optionable

PRTA, VIR, KLRA, and RXRX Headlines

Recent News About These Companies

WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR

September 13 at 4:40 AM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 10, 2026 | americanbankingnews.com

Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR

September 6, 2026 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR

September 4, 2026 | marketbeat.com

Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR

September 3, 2026 | marketbeat.com

Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR

September 2, 2026 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week High - Should You Buy?

September 2, 2026 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Trading 4.8% Higher - Here's What Happened

September 1, 2026 | marketbeat.com

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026 | businesswire.com

Deutsche Bank AG Acquires Shares of 134,258 Vir Biotechnology, Inc. $VIR

August 30, 2026 | marketbeat.com

BlackRock Inc. Purchases New Position in Vir Biotechnology, Inc. $VIR

August 28, 2026 | marketbeat.com

Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & History - Yahoo Finance

August 28, 2026 | finance.yahoo.com

Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR

August 26, 2026 | marketbeat.com

ARCH Venture Management LLC Invests $129.35 Billion in Vir Biotechnology, Inc. $VIR

August 26, 2026 | marketbeat.com

Vir Biotechnology climbs 9% amid post-earnings uptrend

August 25, 2026 | seekingalpha.com

Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1% - Time to Buy?

August 25, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Takes Position in Vir Biotechnology, Inc. $VIR

August 25, 2026 | marketbeat.com

Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum

August 20, 2026 | theglobeandmail.com

Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst

August 19, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRTA, VIR, KLRA, and RXRX Company Descriptions

Kailera Therapeutics NASDAQ:KLRA

$12.70 -0.75 (-5.58%)

As of 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Prothena NASDAQ:PRTA

$8.24 -0.09 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$8.24 0.00 (0.00%)

As of 06:14 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.19 -0.05 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 +0.02 (+0.78%)

As of 07:13 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Vir Biotechnology NASDAQ:VIR

$10.52 +0.08 (+0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$10.54 +0.02 (+0.14%)

As of 06:59 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, VIR, KLRA, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, VIR, KLRA, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, VIR, KLRA, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRTA, VIR, KLRA, and RXRX Company Descriptions

Kailera Therapeutics NASDAQ:KLRA

Prothena NASDAQ:PRTA

Recursion Pharmaceuticals NASDAQ:RXRX

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, VIR, KLRA, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, VIR, KLRA, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, VIR, KLRA, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRTA, VIR, KLRA, and RXRX Company Descriptions

Kailera Therapeutics NASDAQ:KLRA

Prothena NASDAQ:PRTA

Recursion Pharmaceuticals NASDAQ:RXRX

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools